DND-41 In Vitro MTT Assay (Cell Viability) (CAT#: ITS-1122-YF5147)

DND-41

Human

DND-41 was established from the peripheral blood of 13-year-old boy with T-acute lymphoblastic leukemia (T-ALL; type III cortical) in 1977; described to carry CDKN2B (p15INK4B) and CDKN2A (p16INK4A) deletions and TP53 (p53)mutation.

Acute Lymphoblastic Leukemia; ALL

Oncology

In Vitro MTT Assay (Cell Viability)

DND-41-cell based In Vitro MTT Assay (Cell Viability)

The MTT (3-(4,5-dimeth ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is one of most commonly used assays for cancer drug screening. This assay has been very popular among cancer researchers as an initial assay in drug discovery. NAD(P)H-dependent oxidoreductase or dehydrogenases in viable cells can reduce MTT into purple-colored formazan, which can then be solubilized for spectrophotometric analysis.

MTT (3-(4,5-dimeth ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Assay

Cell Viability/Cytotoxicity and Antiproliferative Assays

Uncontrolled proliferation is one of the main features of cancer cells. Cell-based in vitro assays are employed to determine whether test molecules possess direct cytotoxic/antiproliferative effects in cancer cells.

Cell Viability Assay

Cell-based Viability Assays Based on Cellular Enzymes and Proteins